The specific Lp(a)-lowering drugs in development, and the treatments a clinician can use today. Each page carries the mechanism, the trial milestones and the current regulatory status.
NewAmsterdam Pharma / Menarini
Positive CHMP opinion July 2026 (Ubeslo, Evlarco); lowers Lp(a) by about 37 percent
The selective CETP inhibitor lowered Lp(a) by 37 percent (15 nmol/L; 43 percent, 36 nmol/L, at baseline 50 to 150 nmol/L) alongside a 37 percent LDL-C reduction in a pooled analysis of 2,356 phase 3 patients (Nicholls, EHJ 2026). Recommended for EU approval on 24 July 2026 as an LDL-C-lowering therapy; the PREVAIL outcomes trial reports in 2027. Relevant to the many patients below RNA-trial thresholds. See the…
Eli Lilly
Phase 3 outcomes (MOVE-Lp(a), n=10,450, recruiting)
The first oral Lp(a)-lowering agent: a small molecule that blocks the assembly of apo(a) with apoB100 while sparing plasminogen. Up to 65 percent lowering in 14 days in phase 1 (JAMA 2023, single site in the Netherlands) and 82 to 86 percent at 60 to 240 mg daily on an intact-particle assay in KRAKEN (JAMA 2025). MOVE-Lp(a) started September 2025 and runs to 2031.
Eli Lilly
Phase 3 outcomes (ACCLAIM-Lp(a), n=17,300, enrolment complete)
An extended-duration GalNAc siRNA against LPA: a single 608 mg dose kept Lp(a) 94 percent down at day 337 (JAMA 2023) and 400 mg twice a year lowered time-averaged Lp(a) by about 94 percent in ALPACA (NEJM 2025). ACCLAIM-Lp(a), the largest Lp(a) outcomes trial, has finished enrolling and runs to 2029; dosing is about every six months.
Amgen
Phase 3 outcomes (OCEAN(a)-Outcomes, n=7,297) and primary prevention (OCEAN(a)-PreEvent, n=11,000)
A GalNAc-conjugated small interfering RNA that degrades LPA mRNA, given 75 mg subcutaneously every 12 weeks. Lowered Lp(a) by more than 95 percent in OCEAN(a)-DOSE (NEJM 2022) with a long off-treatment tail (JACC 2024). OCEAN(a)-Outcomes started December 2022 with a readout pointed at 2026 to 2027; OCEAN(a)-PreEvent, the first primary-prevention Lp(a) outcomes trial, started August 2025.
Silence Therapeutics
Phase 2 complete; phase 3 outcomes trial awaits a partner
A GalNAc siRNA against LPA that lowered Lp(a) by up to 98 percent after single doses (APOLLO, JAMA 2022) and by more than 80 percent time-averaged over 36 weeks at 300 to 450 mg every 16 to 24 weeks (ALPACAR, JAMA 2024). Silence Therapeutics has said it will only start the phase 3 cardiovascular outcomes study once a partner is secured.
Novartis (licensed from Ionis/Akcea)
Phase 3; first phase 3 result July 2026 (apheresis trial); outcomes trial Lp(a)HORIZON awaited
A GalNAc3-conjugated second-generation antisense oligonucleotide against LPA mRNA, given as 80 mg subcutaneously every 4 weeks. Lowers Lp(a) by about 80 percent (NEJM 2020) and replaced weekly apheresis in 25 of 26 patients in Lp(a)FRONTIERS APHERESIS (EHJ 2026). Lp(a)HORIZON (n=8,323) is the first Lp(a) outcomes trial; readout guided to 2026, not yet announced.
Amgen, Sanofi/Regeneron, Novartis
Approved for LDL-C; lower Lp(a) by 20 to 30 percent as a secondary effect
Monoclonal antibodies lower Lp(a) by a median 25 to 30 percent (inclisiran about 22 percent) and the trial analyses suggest part of their benefit runs through Lp(a): larger absolute risk reductions at high baseline Lp(a) in FOURIER (Circulation 2019) and VESALIUS-CV (Circulation 2026), and alirocumab-induced Lp(a) lowering independently predicting fewer events in ODYSSEY OUTCOMES (JACC 2020, EHJ 2020). Not an Lp(a)…
Extracorporeal (various systems)
Approved and reimbursed for Lp(a) hyperlipoproteinaemia with progressive ASCVD in Germany since 2008; FDA indication in FH
Weekly or biweekly extracorporeal removal of apoB-containing lipoproteins lowers Lp(a) by 60 to 70 percent per session and, in the German Pro(a)LiFe cohort, cut annual cardiovascular event rates from 0.41 to 0.09 (Circulation 2013), sustained over 5 and 12 years (ATVB 2016, Atherosclerosis 2025). Uncontrolled evidence, but for fifteen years the only effective therapy. Lp(a)FRONTIERS APHERESIS (EHJ 2026) showed…